| COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ... The Lancet Oncology 21 (10), 1309-1316, 2020 | 621 | 2020 |
| Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study ER Copson, TC Maishman, WJ Tapper, RI Cutress, S Greville-Heygate, ... The lancet oncology 19 (2), 169-180, 2018 | 412 | 2018 |
| Prospective observational study of breast cancer treatment outcomes for UK women aged 18–40 years at diagnosis: the POSH study E Copson, B Eccles, T Maishman, S Gerty, L Stanton, RI Cutress, ... Journal of the national cancer institute 105 (13), 978-988, 2013 | 223 | 2013 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 178 | 2022 |
| Obesity in breast cancer–what is the risk factor? FR James, S Wootton, A Jackson, M Wiseman, ER Copson, RI Cutress European journal of cancer 51 (6), 705-720, 2015 | 159 | 2015 |
| Herceptin (trastuzamab) in advanced breast cancer J Stebbing, E Copson, S O’reilly Cancer treatment reviews 26 (4), 287-290, 2000 | 157 | 2000 |
| Prediction of single‐nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6 M Raponi, J Kralovicova, E Copson, P Divina, D Eccles, P Johnson, ... Human mutation 32 (4), 436-444, 2011 | 148 | 2011 |
| Understanding of BRCA VUS genetic results by breast cancer specialists BK Eccles, E Copson, T Maishman, JE Abraham, DM Eccles BMC cancer 15, 1-9, 2015 | 132 | 2015 |
| Mindfulness for the self-management of fatigue, anxiety, and depression in women with metastatic breast cancer: a mixed methods feasibility study C Eyles, GM Leydon, CJ Hoffman, ER Copson, P Prescott, ... Integrative cancer therapies 14 (1), 42-56, 2015 | 131 | 2015 |
| Obesity and the outcome of young breast cancer patients in the UK: the POSH study ER Copson, RI Cutress, T Maishman, BK Eccles, S Gerty, L Stanton, ... Annals of Oncology 26 (1), 101-112, 2015 | 110 | 2015 |
| Local recurrence and breast oncological surgery in young women with breast cancer: the POSH observational cohort study T Maishman, RI Cutress, A Hernandez, S Gerty, ER Copson, L Durcan, ... Annals of surgery 266 (1), 165-172, 2017 | 109 | 2017 |
| A review of modifiable risk factors in young women for the prevention of breast cancer AA Daly, R Rolph, RI Cutress, ER Copson Breast Cancer: Targets and Therapy, 241-257, 2021 | 83 | 2021 |
| Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study E Copson, T Maishman, S Gerty, B Eccles, L Stanton, RI Cutress, ... British journal of cancer 110 (1), 230-241, 2014 | 81 | 2014 |
| Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers ER Copson, HE White, JP Blaydes, DO Robinson, PW Johnson, ... BMC cancer 6, 1-6, 2006 | 60 | 2006 |
| A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment J Cave, A Paschalis, CY Huang, M West, E Copson, S Jack, MPW Grocott Supportive Care in Cancer 26, 3337-3351, 2018 | 57 | 2018 |
| The impact of race and ethnicity in breast cancer—disparities and implications for precision oncology KA Hirko, G Rocque, E Reasor, A Taye, A Daly, RI Cutress, ER Copson, ... BMC medicine 20 (1), 72, 2022 | 52 | 2022 |
| Clinical proteomics and breast cancer BA Zeidan, PA Townsend, SD Garbis, E Copson, RI Cutress the surgeon 13 (5), 271-278, 2015 | 51 | 2015 |
| Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19 C Várnai, C Palles, R Arnold, HM Curley, K Purshouse, VWT Cheng, ... JAMA network open 5 (2), e220130-e220130, 2022 | 49 | 2022 |
| The acceptability of addressing alcohol consumption as a modifiable risk factor for breast cancer: a mixed method study within breast screening services and symptomatic breast … J Sinclair, M McCann, E Sheldon, I Gordon, L Brierley-Jones, E Copson BMJ open 9 (6), e027371, 2019 | 46 | 2019 |
| Systematic review of the side effects associated with anti-HER2-targeted therapies used in the treatment of breast cancer, on behalf of the EORTC quality of life group SC Sodergren, E Copson, A White, F Efficace, M Sprangers, ... Targeted oncology 11, 277-292, 2016 | 46 | 2016 |
